Navigation Links
Vion Reports 2007 Fourth Quarter and Year-End Results
Date:3/17/2008

ontinue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward- looking statements included under Item 1A, "Risk Factors" in Vion's Form 10-K for the year ended December 31, 2006 and the Company's Form 10-Q for the quarter ended September 30, 2007. In particular, there can be no assurance as to the results of any of the Vion's clinical trials, that any of these trials will continue to full accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to update arises under law when prior disclosure becomes materially misleading in light of subsequent events, Vion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

COMPANY CONTACT: Vion Pharmaceuticals, Inc.

Alan Kessman, Chief Executive Officer

Howard B. Johnson, President & CFO

(203) 498-4210

VION PHARMACEUTICALS, INC.

(A Development Stage Company)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

Three Months Ended Year Ended

(In thousands, except per share December 31, December 31,

data) 2007 2006 2007 2006

(Unaudited)

Technology license fee revenue $50 $6 $66 $22

Operating expenses:

Clinical trials 2,846 3,087 13,627 13,070

Other research and development 2,673 1,900 10,571 8,414

Total research and


'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
2. Renovis Reports Fourth Quarter and Full Year 2007 Financial Results
3. Warner Chilcott Reports the Death of Its Director James Andress
4. Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
5. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
6. Unigene Restates Policy on Analyst Reports
7. NPS Pharmaceuticals Reports 2007 Financial Results
8. Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook
9. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
10. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
11. MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... James Sherley says he has been working ... cell technology since his days as a principal investigator at ... late 1990’s. Sherley founded the ASCTC as a new ... the intellectual property developed in Sherley’s research over the years ... of Technology (MIT), and more recently as a senior scientist ...
(Date:10/30/2014)... UAE (PRWEB) October 30, 2014 Grace Century ... Dr. James A. Manganello, Chairman of the Board, to the ... Bahamas. The appointment was made by the Ministry of ... September 24th, 2014. , More than a year ... Research Bill , Prime Minister Perry Christie said the government ...
(Date:10/30/2014)... one of the key challenges in the development of ... physicists. , In a paper published today (28 October) ... colleagues show how to make a new type of ... devices, such as high-precision sensors and specialised superfast computers, ... But the methods for trapping these tiny particles are ...
(Date:10/27/2014)... 2014 The Italian company ... and sell its artificial "lower limb", after the ...      (Photo: http://photos.prnewswire.com/prnh/20141027/713097 ) ... the definitive judgement has arrived: Roadrunnerfoot, the small ... accessible hi-tech prostheses with composite materials, has won ...
Breaking Biology Technology:Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 3Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2
... ... space, ... the newest member of its surface disinfection line,CaviWipes in a flat ... slim, flexible packaging and,adhesive-backed strips. Each flat pack contains convenient, durable,nonwoven, ...
... Pharmaceuticals,a division of Wyeth (NYSE: WYE ), ... (FDA) has approved PRISTIQ(TM) (desvenlafaxine), a,structurally novel, once-daily ... major depressive disorder (MDD). Wyeth,expects to begin shipping ... 2008., "We are pleased to be able ...
... Asbestos-Cancer Group: CNN Expose Highlights Urgent Need for ... ... CNN,s recent expose on,asbestos in children,s toys demonstrates the shocking reality ... decades, asbestos was used heavily in Navy ships and shipyards; in,workplaces; ...
Cached Biology Technology:CaviWipes(R): Taking Surface Disinfection to a New Level 2FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 2FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 3FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 4FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 5FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 6FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 7FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 8FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder 9Calling for a Cure 2
(Date:10/31/2014)... Geologists are letting the air out of a nagging mystery ... have long speculated as to why animal species didn,t flourish ... to prosper at the end of the Proterozoic period, about ... stretch before that, when most researchers think there also was ... so great then, after all. , In a study published ...
(Date:10/31/2014)... University of Adelaide-led project has developed a new test ... against the H5N1 strain of avian influenza virus or ... , This is a significant step in the fight ... is widespread in the poultry populations of South East ... concern because of its possible transmission to humans and ...
(Date:10/30/2014)... Mich. – When most animals begin life, cells immediately ... a vital organ. However, mammals, including humans, are special. ... different first choice – to become the protective placenta ... during this critical first step that research from Michigan ... in the current issue of PLOS Genetics ...
Breaking Biology News(10 mins):Lack of oxygen delayed the rise of animals on Earth 2New step towards eradication of H5N1 bird flu 2Identifying the source of stem cells 2
... Biobanks are repositories for tissue samples, usually in ... from surgical procedures. These samples are collected and used ... linked to personal health information regarding the sample donor. ... researchers who want to use them face important questions ...
... The Life Sciences Discovery Fund (LSDF) today announced awards ... therapies and key resources for medical researchers and health-care ... the three programs. The programs will be led ... across the state. Dr. David Flum will work with ...
... MADISON, WI, JUNE 28, 2011 -- The ... provides information needed to sustainably manage agroforestry systems. ... increase yields and also reduce financial and environmental ... that allows for site-specific evaluation of nutrient-production imbalances ...
Cached Biology News:Public prefers limited informed consent process for biobanks 2Public prefers limited informed consent process for biobanks 3Life Sciences Discovery Fund helps launch 3 programs to advance health research and development 2Analyzing agroforestry management 2
... assays utilize the membrane-permeant ester forms ... charged fluorescent beta-lactamase substrates, CCF2 and ... the cell, where cleavage by endogeneous ... their negatively charged forms, thereby trapping ...
... utilize the membrane-permeant ester forms (CCF2-AM ... fluorescent beta-lactamase substrates, CCF2 and CCF4. ... cell, where cleavage by endogeneous cytoplasmic ... negatively charged forms, thereby trapping them ...
1M stock solution (238mg/ml)...
Request Info...
Biology Products: